Oncology

View All

Delveinsight
DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports

DelveInsight expertise over 400+ Indication Active Pharmaceutical Ingredient (API) Reports DelveInsight, leading Market Research and Business Consulting firm has an expertise in providing business solutions to Pharma and biotech companies. DelveInsight has 400+ Indication API reports on wide range of therapeutic ...

Find More

Delveinsight
Chimeric Antigen Receptor T-cell Therapy Landscape

In the field of oncology, no other approach is as attentive as Immunotherapy. Renewed interest in immunotherapy has been driven by Chimeric Antigen Receptor (CAR) T-cell therapy. This emerging approach is (CAR) T-cell technology which is showing great promise in immunotherapy. There are 35+ products in pipeline and...

Find More

Delveinsight
PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015

PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer. DelveIns...

Find More

Delveinsight
Antibody-Drug Conjugates Market Outlook, 2015 Report

264 Antibody-Drug Conjugates in Pipeline!!!! Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the ch...

Find More

Delveinsight
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

Antibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting Cancer Traditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach was also referred to as the carpet-bombing strategy for fighting cancer. Traditional chemotherapy does not discriminate b...

Find More

Delveinsight
DelveInsight’s Gene Therapy Reports: Launched

Immense Growth Potential in the Gene Therapy Market! DelveInsight has launched its Gene Therapy Report: “Gene Therapy Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape”. These Reports are the outcome of very best analytical abilities and diligent market research amalgamated with opin...

Find More

Delveinsight
Gene Therapy’s Emergence: The “New” approach for Huntington’s disease

Many companies have tried over the years to find a way to reverse the course of crippling neurodegenerative disorders like Huntington’s but have failed. Fortunately, Gene therapy has proven to be an answer to a wide range of serious neurodegenerative disorders like Huntington’s, and Parkinson’s etc. The HD gene vs...

Find More

Delveinsight
Are you ready to embrace Gene Therapy?

Gene Therapy: The “Big Value” Market! Gene therapy has been under scientific research for over 2 decades, but viable therapies have yet to gain commercial acceptance due to safety and delivery-related issues. However, Pfizer’s move and some other recent developments in the industry suggest that the therapy may be ...

Find More

Delveinsight
DelveInsight’s Oncology based Gene Therapy Reports

Gene Therapy: The “Cure” for Cancer! About Gene Therapy Gene Therapy involves using drugs that are aimed at specific genes or proteins that are only found in cancer cells or the tissue environment that contributes to cancer growth and survival. Put simply, it injects these genes into the tiny cells, with the help ...

Find More

Delveinsight
Break the Gene Therapy Barrier with DelveInsight’s Gene Therapy Reports

Gene Therapy: The Future is here! Scientific research and clinical trials aren’t glamorous, but they are essential for effective treatments and perhaps ultimately a cure for various debilitating diseases like cancer etc. Gene therapy's potential to revolutionize medicine in the future is exciting, and one day it m...

Find More